1. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W et al (2011) Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13(3):353–361
2. Vecil GG, Lang FF (2003) Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J Neurooncol 65(3):237–246
3. Shewach DS, Zerbe LK, Hughes TL, Roessler BJ, Breakefield XO, Davidson BL (1994) Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1(2):107–112
4. McBride WH (2012) Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma. Future Oncol 8(1):17–20
5. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP (1996) Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103–110